Pharmaceutical giant Pfizer is making a $20 million investment in Israeli firm CytoReason, a developer of computational disease models for drug discovery and development, as part of a wider deal worth up to $110 million over the next five years, the companies announced on September 20.
The deal builds on an existing, multiyear cooperation agreement dating back to 2019 that allows Pfizer to use CytoReason’s digital models of the human immune system and diseases in its pursuit of developing innovative drugs.
Under the terms of the renewed partnership deal, Pfizer will make an equity investment of $20 million, have options to license CytoReason’s platform and disease models in a multiyear commercial deal worth $90 million, and fund additional research projects, bringing the value of the total transaction to $110 million by 2027.
CytoReason says its technologies have provided Pfizer with insights into a number of R&D programs across over 20 diseases including autoimmune disorders such as lupus and inflammatory bowel disease (IBD). IBD is a lifelong, chronic disease that affects the digestive system, and includes Crohn’s disease and ulcerative colitis.
The new research agreement will support the development of additional disease models in new therapeutic areas, the parties said.
“Pfizer has been a strategic partner of CytoReason since 2019, and we are thrilled to scale our collaboration as one of Pfizer’s trusted AI partners for accelerating drug development,” said CytoReason co-founder and CEO David Harel in a company statement.
The partnership will advance “a significant shift in the biotech industry” and help “drive future R&D for pharmaceutical companies as they continue to use machine learning to develop treatments more efficiently,” said Harel.
Founded in 2016, CytoReason developed computational technology that serves as a GPS-like mechanism that navigates the immune system. The machine-learning software collects and combines data from a variety of sources, including in-house data and published research on the immune system and other clinical studies, to discover insights into the biology of diseases.
The technology then builds a digital, computational simulator of the human body that can be used to predict responses to drugs, thus providing direction as to which ones can best benefit patients.
Essentially, CytoReason allows pharmaceutical companies “to develop their drugs on our platform using AI to simulate the response rather than wait for animal trials and then clinical trials,” Harel told The Times of Israel last year. “This also helps to reduce costs.”
Costs, and time, are huge factors in drug discovery and development. On average, it takes billions of dollars and almost a decade to develop new medications, because of the lengthy trials and lab work involved in the process. According to a 2016 study that examined the average R&D amounts for developing new drugs, the costs were found to be between $1.4 billion and $2.8 billion after market approval.
Mikael Dolsten, Pfizer’s chief scientific officer and president of worldwide research, said the company was looking forward to continuing its work with CytoReason’s team of some 80 biologists, bioinformaticians and data engineers, and to “leveraging its cutting-edge platform.”
“CytoReason’s biological data allows us to gain deeper insight into the best drug development pathways for patients, resulting in more informed decisions that are timely and cost-effective,” said Dolsten.
By Ricky Ben-David/ www.TimesofIsrael.com
